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ABSTRACT
Advancement in the field of computational research
has made it possible for the in silico methods to
offer significant benefits to both regulatory needs
and requirements for risk assessments, and phar-
maceutical industry to assess the safety profile of
a chemical. Here, we present ProTox-II that incor-
porates molecular similarity, pharmacophores, frag-
ment propensities and machine-learning models for
the prediction of various toxicity endpoints; such as
acute toxicity, hepatotoxicity, cytotoxicity, carcino-
genicity, mutagenicity, immunotoxicity, adverse out-
comes pathways (Tox21) and toxicity targets. The
predictive models are built on data from both in
vitro assays (e.g. Tox21 assays, Ames bacterial muta-
tion assays, hepG2 cytotoxicity assays, Immunotox-
icity assays) and in vivo cases (e.g. carcinogenicity,
hepatotoxicity). The models have been validated on
independent external sets and have shown strong
performance. ProTox-II provides a freely available
webserver for in silico toxicity prediction for tox-
icologists, regulatory agencies, computational and
medicinal chemists, and all users without login at
http://tox.charite.de/protox II. The webserver takes a
two-dimensional chemical structure as an input and
reports the possible toxicity profile of the chemical
for 33 models with confidence scores, and an over-
all toxicity radar chart along with three most similar
compounds with known acute toxicity.
INTRODUCTION
An early assessment of the toxic properties for a chemical
structure is not only important in the field of drug discovery
but also for the regulatory decision making bodies such as
European Medicines Agency (EMA), U.S. Food and Drug
Administration (FDA) and environmental health protec-
tion agencies like U.S. Environmental Protection Agency
(EPA), and European Environment Agency (EEA) (1).
With the ever-rising number of chemicals and an exponen-
tial number of their combinations as mixtures, our expo-
sure to chemicals also increases. Interaction with chemi-
cals is an integral part of our everyday life as we are liv-
ing in a highly active chemical environment that includes
everything from the food that we eat, the medicines we are
prescribed, the cosmetics we use as to the air we breathe.
However, such exposure can be both harmful and benefi-
cial depending on the amount and duration of the chemi-
cal exposure. Thus, it is important to validate the toxic po-
tential of the chemicals and their combination experimen-
tally (2). However, due to several challenges such as time,
cost and ethical concerns with respect to animal trials, it is
impossible to test all these chemicals on experimental plat-
forms. Thus, in silico toxicity is highly evolving as an in-
tegral platform for the prediction of toxicity of chemicals
that could be harmful to humans, animals, plants, and en-
vironments (3). The aim of in silico toxicity models is to
complement the existing in vitro toxicity methods to pre-
dict toxicity effects of chemicals, thereby minimizing the
time, the need of animal testing and cost associated with
it. In silico toxicity model incorporates the knowledge from
various fields such as toxicology, biostatistics, systems biol-
ogy, computer science and many other relevant disciplines
(1).Toxicity of a chemical can be measured in terms of tox-
icity endpoints, such as mutagenicity, carcinogenicity and
many other endpoints. It can be further measured both
quantitatively such as LD50 (lethal dose) values, and qual-
itatively, such as binary (active or inactive) for certain cell
types and assays or indication area such as cytotoxicity, im-
munotoxicity and hepatotoxicity (3). One of the most im-
portant fodders for in silico models is the information-rich
data. The data sources like DSSTox (Distributed Structure-
Searchable Toxicity) (4), CEBS: a comprehensive annotated
database of toxicological data (5), LiverTox: a database of
clinical and research information on DILI (Drug Induced
Liver Injury) (6), and Tox21 datasets; have largely sup-
ported the interpretation of information from large-scale
high-throughput assays with hundreds to thousands of bio-
logical endpoints, such as identification of toxicity pathways
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(7,8). The toxicology in the 21st Century (Tox21) (an initia-
tive by the federal collaboration of National Institute of En-
vironmental Health Sciences, the EPA, and the FDA), has
greatly supported the development of computational meth-
ods for the assessment of toxicity of chemicals, fostering
the vision of transforming toxicology into a predictive sci-
ence (8,9). Several computational models have been devel-
oped to predict the toxicity of chemicals (8,10,11). Initially,
to make rodent acute toxicity prediction platform available
to a larger community, both to experimental researchers
as well as computational toxicologists, ProTox: webserver
for the prediction of rodent oral toxicity was published in
the year 2014 (12). ProTox methods performed compara-
tively better than commercial software like Discovery Stu-
dio’s TOPKAT (Toxicity Prediction by Komputer Assisted
Technology; Accelrys, Inc., USA) (http://accelrys.com/)
as well as freely accessible tool like Toxicity Estimation
Software Tools (T.E.S.T.) developed by the U.S. Environ-
mental Protection Agency (https://www.epa.gov/chemical-
research/toxicity-estimation-software-tool-test). Addition-
ally, webservers partially freely available for the community
such as the AdmetSAR which includes different types of
prediction models based on QSAR methods has also been
beneficial for the community (13).
The ProTox-II webserver provides several advantages
over existing computational models. ProTox webserver, in-
cludes both chemical and molecular target knowledge. A
novelty of the ProTox-II webserver is that the prediction
scheme is classified into different levels of toxicity such oral
toxicity, organ toxicity (hepatotoxicity), toxicological end-
points (such as mutagenicity, carcinotoxicity, cytotoxicity
and immunotoxicity), toxicological pathways (AOPs) and
toxicity targets thereby providing insights into the possi-
ble molecular mechanism behind such toxic response. The
new version, ProTox-II incorporates molecular similarity,
pharmacophore based, fragment propensities, most com-
mon features and machine learning models for prediction
of various toxicity endpoints. ProTox-II consisting of 33
models is a freely available computational toxicity predic-
tionwebserver enabling the prediction of the largest number
of toxicological endpoints to date.
ProTox-II PLATFORM
Input parameter
The user interface of the ProTox-II is easy-to-use and self-
explanatory. To predict potential toxicities associated with
a chemical structure, the user can type the name of the
compound or insert the SMILES (Simplified Molecular-
Input Line-Entry System) string of the compound. Addi-
tionally, the user has the possibility to draw the chemical
structure with the help of the chemical editor (https://www.
chemdoodle.com/). Furthermore, the integrated PubChem
search (https:/pubchem.ncbi.nlm.nih.gov/) allows the user
to search for chemical structures using the compound name.
Optionally, the user may select additional models or all
models for prediction. If the user does not specify any ad-
ditional models, the webserver computes the prediction for
acute toxicity and toxicity targets by default.
Output information
The prediction results for the acute toxicity and toxicity tar-
gets are generated instantly. The result page will show the
predicted median lethal dose (LD50) in mg/kg weight, toxi-
city class, and prediction accuracy aswell as average similar-
ity along with three most similar toxic compounds from the
dataset with the known rodent oral toxicity value. The pre-
dicted toxicity targets information, if available will be shown
with the name of the target as well as the average fit and sim-
ilarity of the input compound with the pharmacophore and
known ligands of the respective targets. Furthermore, if the
user selects additional models, the result page will show the
prediction outcomes with confidence score for each model
in a table. A web link to access the results will be provided
to the user, in case the prediction results cannot be shown
immediately. These prediction results are also displayed as a
toxicity radar plot comparing the average confidence score
of the active compounds in the training set of each model,
to that of the input compound (Figure 1). This plot can be
assessed using the ‘Open Toxicity Radar Chart’ link that
will appear on the result page, once the computation is com-
plete. The same chart can be opened by using the thumbnail
below the Toxicity Models Report. More detailed informa-
tion with an example compound output is made available
on the ProTox-II webserver.
METHODS
The ProTox-II platform is divided into a five different clas-
sification steps: (i) acute toxicity (oral toxicity model with
six different toxicity classes); (2) organ toxicity (one model);
(3) toxicological endpoints (four models); (4) toxicological
pathways (12 models) and (5) toxicity targets (15 models).
Here, we provide short description for each of the models
available on the ProTox-II server. A detailed information
with references, performance scores and frequency distri-
bution of most common features present in the training set
(both for active and inactive) molecule are available under
model info on the ProTox-II webserver. A complete descrip-
tion on the number of data sets used in this study is provided
as Supplementary Table S1.
Acute toxicity
Oral toxicity. The acute toxicity models are developed
based on chemical similarities between compounds with
known toxic effects and the presence of toxic fragments as
explained in our previous paper (12). The acute toxicity
data are extracted from the updated version of the in-house
database SuperToxic (14).
Toxicity targets
The prediction of toxicity targets is based on 15 different
targets from theNovartis in vitro safety panels of the protein
targets linked to adverse drug-reactions (15) as reported in
our previous work (12).
Organ toxicity
Hepatotoxicity. Drug-induced hepatotoxicity is a signifi-
cant cause of acute liver failure and one of the major rea-
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sons for the withdrawal of drugs from the market (16).
Drug-induced liver injury (DILI) is either a chronic pro-
cess or a rare event. However, prediction of DILI is impor-
tant and one of the safety concerns for the drug develop-
ers, regulators and clinicians (17). The data for the predic-
tion of DILI are taken from DILIrank (18) and the NIH
LiverTox database (6). The ProTox-II hepatotoxicity pre-
diction model has a balanced accuracy of 82.00% on cross-
validation and 86.00% on external validation. The AUC–
ROC scores of cross-validation and external validation are
0.86 and 0.91 respectively (Tables 1 and 2). The kappa value
is 0.69 for the model (Tables 1 and 2).
Toxicological endpoints
Carcinogenicity. Chemicals that can induce tumors or in-
crease the incidence of tumours are referred as carcinogens.
(19). The data for the prediction of carcinogenicity are col-
lected from the Carcinogenic Potency Database (CPDB)
(20) and CEBS database (5). The ProTox-II carcinogenic-
ity prediction model has a balanced accuracy of 81.24%
on cross-validation and 83.30% on external validation. The
AUC–ROC scores of cross-validation and external valida-
tion are 0.85 and 0.87 respectively. The kappa value is 0.69
for the model (Tables 1 and 2).
Mutagenicity. Chemicals that cause abnormal geneticmu-
tations such as changes in the DNA of a cell are referred as
mutagens (21). Such changes can cause harm to the cells
and result in certain disease, e.g. cancer. ProTox-II, muta-
genicity prediction is based on the benchmark data set from
Ames test (22) as well as CEBS database (5). The ProTox-
II mutagenicity prediction model has a balanced accuracy
of 84.00% on cross-validation and 85.00% on external val-
idation. The AUC–ROC scores of cross-validation and ex-
ternal validation are 0.90 and 0.91 respectively. The kappa
value is 0.69 for the model (Tables 1 and 2).
Cytotoxicity. Prediction of cytotoxicity is important to
screen compounds that can cause undesired and desired
cell damage, the latter as in the case of the tumour cells
(1). The ProTox-II cytotoxicity model is based on data ex-
tracted from the Chemical European Biology Laboratory
(ChEMBL) database (23). All compounds with an IC50
value of less than or equal to 10 M in the in vitro toxic-
ity assay against HepG2 cells are considered as positively
cytotoxic. The ProTox-II cytotoxicity prediction model has
a balanced accuracy of 85.00% on cross-validation and
83.60% on external validation. The AUC–ROC scores of
cross-validation and external validation are 0.89 and 0.90
respectively. The kappa value is 0.69 for the model (Tables
1 and 2).
Immunotoxicity. The adverse effect of xenobiotics on the
immune system is called immunotoxicity (24). The immuno-
toxicity model is based on immune cell cytotoxicity data
obtained from the U.S. National Cancer Institute’s (NCI)
public database. Growth inhibition (GI50) values from the
B-cell line RPMI-8226 are used and compounds with GI50
values below 10Mare defined as toxic (24). The ProTox-II
immunotoxicity prediction model has a balanced accuracy
of 74.00% on cross-validation and 70.00% on external val-
idation. The AUC–ROC scores of cross-validation and ex-
ternal validation are 0.76 and 0.74 respectively. The kappa
value is 0.35 for the model (Tables 1 and 2).
Toxicological pathways
Toxicology in the 21st Century (Tox21) platform, the US
toxicology initiative whichwas started in 2008, provides a li-
brary of 10 000 chemical data, screened in high-throughput
assays against a panel of 12 different biological target-based
pathways, that involve two-major groups of adverse out-
come pathways (AOPs): the nuclear receptor pathway and
the stress response pathway. ProTox-II, prediction of chem-
ical compounds active in toxicological pathways is based on
the Tox21 dataset (11,25).
Nuclear receptor signaling pathways. There are seven
target-pathway based models under nuclear receptor sig-
naling pathways: aryl hydrogen receptor (AhR), androgen
receptor (AR), androgen receptor ligand binding domain
(AR-LBD), aromatase, estrogen receptor alpha (ER), es-
trogen receptor ligand binding domain (ER-LBD), and
peroxisome proliferator activated receptor gamma (PPAR-
Gamma). All themodels have a balanced accuracy of>80%
and AUC–ROC values within a range of 0.75–0.90 for both
cross-validation and external validation. The kappa values
are in a range of 0.60–0.80 (Tables 1 and 2).
Stress response pathways. There are five target-pathway
based models under stress response pathways: Nuclear fac-
tor (erythroid-derived 2)-like 2/antioxidant responsive el-
ement (ARE), heat shock factor response element (HSE),
mitochondrial membrane potential (MMP), phosphopro-
tein tumor suppressor (p53), and ATPase family AAA
domain-containing protein 5 (ATAD5). All themodels have
a balanced accuracy of>80% andAUC–ROCvalues within
the range of 0.80–0.90 for both cross-validation and exter-
nal validation. Except for HSE the value for ROC–AUC is
0.79. The kappa values are in a range of 0.60–0.80 (Tables
1 and 2).
Prediction models
All the newly added prediction models on the ProTox-II
platform are based onmachine learning algorithms. ARan-
dom Forest (RF) algorithm (26) is used to construct the
classification and prediction models for hepatotoxicity, cy-
totoxicity, mutagenicity, and carcinogenicity. TheRF-based
models are constructed using 500 decision trees and GINI
index criterion. The advantage of using RF-based classifier
is that it tends to avoid overfitting.
For the construction of theTox21 based toxicological
pathway prediction, an ensemble approach is used includ-
ing RF and Support VectorMachine (SVM) classifiers. The
radial basis function (RBF) is used as kernel function for
the SVM algorithm. Immunotoxicity prediction model is
based on Bernoulli–Naive Bayes algorithm, as explained in
the published work (24).
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Here, two different fingerprints are used:MACCSmolec-
ular fingerprints-166 bits andMorgan circular fingerprints-
2048 bits (http:/www.rdkit.org/). These two fingerprints
have shown an optimal performance for prediction of chem-
ical activity (11,24).
Additionally, a selective oversampling of minority class
is introduced in the construction of the models. For each
of the prediction end-points, the active (positive) and inac-
tive (negative) data are fragmented using RECAP (27) and
ROTBONDS (28) fragmentation methods. The propensity
score (PS) (12) for each of the uniquely occurring fragments
in both the sets is computed. Only those molecules having
the highest propensity scores for fragments conserved for
the active class are oversampled and added into model con-
struction. The same ratio of active and inactive compounds
was maintained for all the folds of cross-validation, using
the fragment-based similarities between the compounds.
The prediction models are based on python program-
ming language. Machine learning packages like scikit-learn
(http:/scikit-learn.org) and cheminformatics package RD-
Kit (http:/www.rdkit.org/) are used for the model imple-
mentation. All data are standardized using KNIME (29).
A template script (Sample API script http://tox.charite.de/
protox II/simple api.py) has been provided under the de-
scription ‘using the API’ on the FAQ section of the ProTox-
II webserver.
METHODS VALIDATION
All the new models are validated using fragment-based
CLUSTER 10-fold cross-validation. The data was divided
using fragment similarity based sampling method and en-
suring the active and inactive ratios are constant into 10
sets; 9 of which were used to train themodel and 10th to val-
idate the model. Additionally, external sets (which was pre-
viously not introduced in the training set) was used for ex-
ternal validation of the models. All the models are assessed
on the following performance measures:
• Balanced accuracy is defined as the (sensitivity +
specificity)/2 which also equals to 1/2[true positive/(true
positive + false negative) + true negative/(true negative +
false positive)]
• The area under the curve (AUC) of a receiver operating
characteristic (ROC) curve plots sensitivity versus 1 –
specificity at different thresholds. The AUC–ROC has
been used as an effective measure for binary classifiers
trained on imbalanced data set (having minority and ma-
jority class) (30).
• The kappa index measures the quality of binary classifi-
cation models. The kappa index ranges between 0 (less
significant) to 1(perfect) (31).
Application case
To illustrate the functionalities as well as possible applica-
tion of the ProTox-II webserver, we have selected two differ-
ent examples: one is an approved drug (Etonogestrel) and
another is a withdrawn drug (Tolcapone).
Etonogestrel is an approved drug and is used in hor-
monal contraceptives. Toxicology of progestogens has been
reported in studies (32). Using our ProTox-II webserver,
Etonogestrel has been predicted as Toxicity class 5 for acute
oral toxicity with LD 50 value of 5000mg/kg, with an aver-
age similarity of 92.31% and prediction accuracy of 72.9%.
The organ toxicity (hepatotoxicity) of etonogestrel is pre-
dicted with a confidence score of 0.68 and it is predicted
active for five different toxicological pathways such AR-
LBD, NR-AR, ER-LBD, ER and SR-ARE with high con-
fidence scores of 0.94, 0.96, 0.73, 0.76 and 0.57 respectively.
Additionally, three different toxicity targets (Androgen Re-
ceptor, Amine Oxidase A, Progesterone Receptor A) are
predicted with probable binding. Etonogestrel has shown
Figure 1. Application case: Tolcapone (a withdrawn drug) is considered as an input structure, predicted using 33 models with respective confidence
scores, and prediction results are provided as an overall toxicity radar chart. Tolcapone is predicted to be active for seven endpoints, connecting different
layers of the ProTox-II classification scheme.
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Table 1. Cross-validation results for the newly included models in the ProTox-II platform in terms of balanced accuracy, AUC–ROC and kappa value
Models Balanced accuracy (%) AUC–ROC Kappa Sensitivity (%) Specificity (%)
Organ toxicity
DILI 82.00 0.86 0.69 75.00 89.00
Toxicity endpoints
Mutagenicity 84.00 0.90 0.70 83.00 85.00
Carcinogenicity 81.24 0.85 0.69 80.00 81.00
Cytotoxicity 85.00 0.89 0.65 92.00 78.00
Immunotoxicity 75.00 0.76 0.35 69.50 79.50
Toxicological pathways
nr-ahr 91.00 0.89 0.80 87.00 94.00
nr-ar 93.00 0.84 0.75 89.00 97.00
nr-ar-lbd 89.00 0.87 0.76 79.50 97.00
nr-aromatase 92.00 0.86 0.79 78.00 96.00
nr-er 90.00 0.75 0.71 85.00 95.00
nr-er-lbd 89.00 0.85 0.73 83.00 95.00
nr-ppar-gamma 92.00 0.81 0.71 86.00 97.00
sr-are 91.00 0.84 0.69 85.00 97.00
sr-hse 90.00 0.79 0.73 89.00 91.00
sr-mmp 91.00 0.90 0.74 82.50 96.50
sr-p53 89.00 0.84 0.74 83.00 95.00
sr-atad5 89.00 0.84 0.71 81.50 96.50
Table 2. External validation results for the newly included models in the ProTox-II platform in terms of balanced accuracy, AUC–ROC and kappa value
Models Balanced accuracy (%) AUC–ROC Kappa Sensitivity (%) Specificity (%)
Organ toxicity
DILI 86.00 0.91 0.66 81.00 90.00
Toxicity endpoints
Mutagenicity 85.00 0.91 0.71 83.00 87.00
Carcinogenicity 83.30 0.87 0.65 79.00 78.00
Cytotoxicity 83.60 0.90 0.60 93.00 74.00
Immunotoxicity 70.00 0.74 0.29 65.00 74.00
Toxicological pathways
nr-ahr 91.00 0.90 0.75 74.00 97.00
nr-ar 86.00 0.73 0.73 81.00 91.00
nr-ar-lbd 83.00 0.75 0.72 76.00 90.00
nr-aromatase 89.00 0.75 0.79 79.00 97.00
nr-er 91.00 0.79 0.71 85.50 96.50
nr-er-lbd 89.00 0.80 0.75 79.50 97.50
nr-ppar-gamma 85.00 0.84 0.73 73.00 96.00
sr-are 87.00 0.79 0.72 73.00 97.00
sr-hse 86.00 0.87 0.75 80.00 92.00
sr-mmp 91.00 0.92 0.78 86.00 95.00
sr-p53 89.00 0.87 0.79 80.50 96.00
sr-atad5 84.00 0.80 0.78 73.00 95.00
binding to Progesterone receptor andAndrogenReceptor at
1uM. This is indeed interesting, as Etonogestrel is classified
under relatively less harmful acute toxicity class; however, it
has been predicted to be hepatotoxic and at the same time,
active for five toxicological pathways and three toxicity tar-
gets (Supplementary material S3). Providing insight though
etonogestrel is structurally safe compound, however, it’s in-
teractionwith certainmolecular targetsmight result in toxic
response.
Tolcapone, a catechol o-methyltransferase inhibitor and
a withdrawn drug serves as an interesting example of a
chemical compound which tends to connect different pre-
diction classes designed under ProTox-II method (16). Tol-
capone is reportedwith a toxicity class 4 for acute oral toxic-
ity with LD 50 value of 1600mg/kg, with an average similar-
ity of 100.00% and prediction accuracy of 100.00%. The or-
gan toxicity (hepatotoxicity) of Tolcapone is predicted with
a confidence score of 0.79 and toxicological endpoint (im-
munotoxicity) with a confidence score of 0.52 (33). Addi-
tionally, it is predicted to be active for MMP toxicological
pathway with a confidence score of 0.99 (34). Amine Oxi-
dase A and Prostaglandin G/H Synthase 1 are predicted as
toxicity targets with lowbinding probability (Figure 1). This
example indeed represents, that there is a possibility that a
compound can be active for multiple toxicity endpoints and
thereby resulting in severe toxic effects (Figure 1).
CONCLUSIONS AND FUTURE UPDATES
Here, we present ProTox-II which incorporates molecular
similarity for acute toxicity prediction, pharmacophore-
based models for 15 toxicity targets, fragment propensi-
ties and machine learning models for 17 different toxicity
end points. To the best of our knowledge, ProTox-II is the
freely available computational toxicity webserver enabling
the prediction of the largest number of toxicity endpoints
consisting of 33 models. A novelty of the updated ProTox-
II webserver is that the prediction scheme is classified into
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different levels of toxicity such oral toxicity, organ toxic-
ity (hepatotoxicity), toxicological endpoints (such as muta-
genicity, carcinotoxicity, cytotoxicity and immunotoxicity),
toxicological pathways (AOPs) and toxicity targets thereby
providing insights into the possible molecular mechanism
behind such toxic response. When compared with other
standard published models, all the models of the ProTox-II
platform performed from the range of comparatively good
to better in some cases. Though, it is worth mentioning
that due to differently processed training sets, and algorithm
parameters as well as molecular descriptors selections and
sampling methods considering different thresholds, a com-
plete comparison of all the models are not feasible. How-
ever, a fair comparison using performance measures like ac-
curacy and AUC–ROC has been provided as Supplemen-
tary Table S2.
We believe that in the process of toxicity analysis extend-
ing to drug discovery, ProTox-II in silico prediction plat-
form will help to initiate focused experimental follow-up
studies and to enhance hit selection and lead optimization
process. Additionally, ProTox-IImethods have the potential
to support risk assessments for regulatory decisions such as
to create novel hypotheses and get insights to the mecha-
nisms of toxicity.
In future, ProTox-II will focus on methods development
to foster better characterization of clinically relevant ad-
verse effects based on published knowledge and relevant
chemical-target-side effect and adverse outcome pathways
networks. The next evolutionary step will be considering
species and inter-individual genetic differences. Addition-
ally, to maintain the high standard of the ProTox-II plat-
form, regular updates are planned and will be executed on
a quarterly basis. Furthermore, new data will be added to
the existing models when available and new endpoints like
genotoxicity, nephrotoxicity, neurotoxicity, and cardiotoxi-
city as well as food allergy prediction will be added.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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